Table 2.
Antiretroviral treatments exposure during follow-up
| eGFR (ml/min/1.73m2) | ||||
|---|---|---|---|---|
| ≥ 90 N = 28,289(81.4%) |
60–89 N = 5645 (16.2%) |
< 60 N = 819 (2.4%) |
Total N = 34,753 |
|
| AZT based cART without PI, n(%) | 13,737 (48.6) | 2703 (47.9) | 205 (25.0) | 16,645 (47.9) |
| AZT based cART + PI, n(%) | 2492 (8.8) | 521 (9.2) | 48 (5.9) | 3061 (8.8) |
| TDF based cART without PI, n(%) | 7708 (27.3) | 1653 (29.3) | 276 (33.7) | 9637 (27.7) |
| TDF based cART + PI, n(%) | 1645 (5.8) | 284 (5.0) | 2 (0.2) | 1931 (5.6) |
| d4T based cART without PI, n(%) | 1890 (6.7) | 318 (5.6) | 71 (8.7) | 2279 (6.6) |
| d4T based cART + PI, n(%) | 274 (0.9) | 39 (0.7) | 0 | 313 (0.9) |
| ABC or ddI based cART + PI, n(%) | 395 (1.4) | 57 (1.3) | 16 (2.0) | 468 (1.3) |
| ABC or ddI based cART without PI, n(%) | 148 (0.5) | 70 (1.0) | 201 (24.5) | 419 (1.2) |
eGFR estimated Glomerular Filtration Rate, cART combination Antiretroviral Therapy, AZT Zidovudine, PI protease inhibitor, TDF Tenofovir Disoproxil Fumarate, d4T Stavudine, ABC abacavir